Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEDICATION-1 pembrolizumab dose tapering trial in advanced non-small cell lung cancer
NL-OMON60078Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Reduced-dose pembrolizumab with Standard-of-care pembrolizumab (2 arms). Primary endpoint: Overall survival rate at 1 year. Started Sep 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60078.